Definium Therapeutics, Inc. (DFTX)
NASDAQ: DFTX · Real-Time Price · USD
21.27
+0.29 (1.38%)
At close: Apr 28, 2026, 4:00 PM EDT
21.20
-0.07 (-0.33%)
After-hours: Apr 28, 2026, 6:41 PM EDT
Definium Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Definium Therapeutics stock have an average target of 38.5, with a low estimate of 25 and a high estimate of 70. The average target predicts an increase of 81.01% from the current stock price of 21.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Definium Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|
| Strong Buy | 1 | 2 | 4 |
| Buy | 2 | 2 | 4 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 3 | 4 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $23 → $30 | Buy | Maintains | $23 → $30 | +41.04% | Apr 22, 2026 |
| Stifel | Stifel | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +41.04% | Apr 17, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $38 | Strong Buy | Maintains | $25 → $38 | +78.66% | Apr 16, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $49 | Buy | Initiates | $49 | +130.37% | Apr 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $55 → $70 | Strong Buy | Maintains | $55 → $70 | +229.10% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
31.74M
EPS This Year
-1.99
from -2.06
EPS Next Year
-1.82
from -1.99
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 200.0M | ||||||
| Avg | n/a | 31.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.68 | -0.56 | ||||||
| Avg | -1.99 | -1.82 | ||||||
| Low | -2.45 | -2.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.